Nanosonics delivers maiden full-year profit on back of strong sales growth
Provider of decontamination products to the healthcare industry, Nanosonics (ASX:NAN), announced on Wednesday that it had recorded a maiden full-year profit of $122,000. The business has gained significant momentum over the last six months, evidenced by the fact that the group generated a profit of $3.4 million in the second half of fiscal 2016.
Consequently, the company appears to now be squarely on the front foot with a portfolio of decontamination products and established proprietary technology placing it well to grow sales in global markets where it is already represented, as well as entering new regions.
Scott Power from Morgans CIMB was impressed with the result and following a meeting with management yesterday he made upward adjustments to projected contributions from the company’s higher margin consumables business, as well as increasing the anticipated installed base from 8700 units to 10,000 units.
This would imply growth of 25% in fiscal 2017 and 20% thereafter. While this would result in a near-term increase in the group’s cost base, the result relative to his current forecasts for fiscal 2017 is earnings neutral and 4% accretive in 2018.
Power is forecasting Nanosonics to generate a profit of $7 million in fiscal 2017, increasing to $18.5 million in 2018, representing earnings per share of 6 cents. He sees exponential growth occurring thereafter with earnings per share doubling again in fiscal 2019.
While there appeared to be an anticipation of an upcoming strong result as Nanosonic’s shares increased approximately 20% from circa $2.40 in mid-July to yesterday’s closing price of $2.80, Power sees scope for further share price upside, and following the result he increased his price target from $2.73 to $3.04.
It should be noted that broker recommendations, forecasts and price targets are not necessarily an indication of the company’s future performance and as such should not form the basis of an investment decision. Furthermore, historical share price performance is not an indicator of a company’s future trading patterns and should not form the basis of an investment decision.
Nanosonics chief executive, Michael Kavanagh, pointed to several developments occurring in the health industry which suggest there will be increasing demand for its medical instrument decontaminating products.
He is of the view that adoption of the group’s products has strengthened with the publication of a number of papers including evidence demonstrating that the group’s Trophon technology is the only proven technology to kill human papillomavirus (HPV).
Kavanagh also noted that new guidance had been published in Scotland requiring high-level disinfection for all semi-critical ultrasound examinations with expectations new guidance will be published in the UK in the first quarter of fiscal 2017.
It has been historically the case that industry developments such as these provide share price momentum for the group. The other development to monitor is the company’s entry into new markets with management confirming yesterday that it was in advanced negotiations with a number of countries in the Middle East.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.